Development o f No vet Fomndatians.... References

176

Aggarwal, B. B. (2,008). "Prostate cancer and curcumin: add spice to your life." Cancer

Biol Ther 7(9): 14364 440,

Ahmad, Z., R. Pandey, et al. (2006). "Pharmacokinetic and pharmacodynamic

behaviour of antituberciilar drugs encapsulated in alginate nanoparticles at two

doses," Intenuitional Journal of Antimicrobial Agents 27(5): 409-416.

Alt, S., A. Ahmad, et al. (2010). "Gemcitabine sensitivity can be induced in pancreatic

cancer cells tlirough modulation of rniR-200 and miR-2f expression by

curcumin or its analogue CDF." Cancer Res 70(9): 3606-3617.

Allemann, E., R. Gurny, et al. (1992). "Preparation of aqueous polymeric

nanodispersions by a reversible salting-out process: influence of process

parameters on particle size." Int. J. Pharm. 87(1-3): 247-253.

Anarid, P., A. B, Kunnumakkara, et al. (2007). "Bioavailability of curcumin; problems

and promises." Mol Pharm 4(6); 807-818.

Anand, P., H. B. Nair, et al. (2010). "Design of curcumin-loaded PLGA nanoparticles

formulation with enhanced cellular uptake, and increased bioactivity in vitro

and superior bioavaiiability in vivo." Biochem Phannacol 79(3): 330-338.

Anand, P., C. Sundaram, et al. (2008). "Curcumin and cancer: an "old-age" disease w ith

an "age-old" solution." Cancer Lett 267(1); 133-164.

Ansari, M. .T„ S. Ahmad, et al. (2005). "Stability-indicating HPTLC determination of

curcumin in bulk drug and pharmaceutical formulations." J Pharm Biomed Anal 39(1-2): 132-138.

Anuchapreeda, S., P. Limtrakiil, et ai. (2006). "Inhibitory effect of curcumin on WTl

gene expression in patieiV leukemic cells." Arch Pharm Res 29(1); 80-87.

Arbos, P., M. A. Campanero, et al. (2004). "Nanopaiticles with specific bioadhesive

properties to circumvent the pre-systemic degradation of fluorinated

pyrimidines." J. Control. Release 96(1): 55-65.

Arun, N. and N. Nalini (2002). "Efficacy of turmeric on blood sugar and polyol

pathway in diabetic albino rats." Plant Foods Hum Nutr 57(1): 41-52.

Atsumi, T., S. Fujisawa, et al. (2005). "Relationship between intracellular ROS

production and membrane mobility in curcumin- and tetrahydrocurcumin-

treated human gingival fibroblasts and human submandibular gland carcinoma

cells." Oral Pis 11(4): 236-242.

Development o f Novel Formulations.. ..References

l l i lR e fe re n e e s

..~ T t7" ~

Development o f Novel Fonnulaiions.... References

At.sumi, T., K. Tonosaki, et al. (2006). "Induction of early apoptosis and ROS-generation activity in human gingival fibroblasts (HGF) and human

submandibular gland carcinoma (HSG) cells treated with curcuniin." Arch Oral

Biol 51(10): 913-921.

Attwood, D. and A. T. Florence (1983). Surfactant systems: tlieir chemistry, pharmacy

and biolQ?j:v. London, Chapman and Hall.

Balachandran, P. and R. Govindarajan (2005). "Cancer-an ayurvedic perspective."

PlKirmacol Res 5 J (1): 19-30.

Balakrishnan, P., B. J. Lee, ct al. (2009). "Enhanced oral bioavailability of Coenzyme

QIO by seif-emulsifying datg delivery systems." International journal of

pharmaceutics 374( 1 -2): 66-72.

Barichello, J. M., M. Morishita, et al. (1999). "Absorption of insulin from Pluronic F-

127 gels following subcutaneous administration in rats." Int. J. Pharm. 184(2);

189498.

Bava, S. V., V. T. Puliappadamba, et ai. (2005). "Sensitization of taxoHnduced

apoptosis by curcumin involves dov\/n-regulation of nuclear factor-kappaB and

the serine/threonine kinase Akt and is independent of tubulin polymerization." J

Biol Chem 280(8): 6301^6308.

Bhakuni, D. S., M. L. Dhar, et al. (1969). "Screening of Indian plants for biological

activity. II." Indian J Ext) Biol 7(4): 250-262.

Bisht, S., G. Feldmann, et ai. (2007). "Polymeric nanoparticle-encapsulated curcumin

("nanocurcumin"): a novel strategy for human cancer therapy." J

Nanobiotechnology 5: 3.

Borhade, V., H. Nair, et al. (2008). "Design and evaluation of self-microemulsifying

drug delivery system (SMEDDS) of tacrotimus." AAPS PharmSciTcch 9(1):

13-21.

Cai, X. Z., J. Wang, et al. (2009). "Curcumin suppresses proliferation and invasion in

human gastric cancer cells by downregulation of PAKl activity and cyclin D1

expression." Cancer Biol Ther 8(14): 1360-1368.

Camacho-Barquero, L., I. Villegas, et al. (2007). "Curcumin, a Curcuma longa

constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS

expression in chronic experimental colitis." Int Immunopharmacol 7(3): 333-

342.

178

DevcUipweit! o f Novel Formulations....References

c,’ao, F. L,., Y. W. Xi, et al. (2009). "fPrepai'atiori and characterization of curcumin

loaded gelatin microspheres for lung targeting]." Zhong Yao Cat 32(3); 423-

426.

Carino, G. P., J. S. Jacob, et al. (2000). "Nanosphere based oral insulin delivery," J.,

Control. Release 65(1-2): 261-269.

Ciien, C., X. Huang, et a!. (2010). "Anti-prolifcration and anti-angiogene-sis of

curcumin-K30 solid dispersion." Zhong Nan Da Xue Xiie Bao Yi Xue fiati

35(10): 1029.1036.

Chen, M. L, (2008), "Lipid excipients and delivery systems for pharmaceutical

development: a regulatory perspective." Adv Drug Deliv Rev 60(6): 768-777.

Cheng, A. L., C. H. Hsu, et al. (2001). "Phase I clinical trial of curcumin, a

chemopreventive agent, in patient,s with high-risk or pre-malignant lesions."

Anticancer Res 21(4B): 2895-2900.

Chin, S. F,, K. S. Iyer, et al. (2009). "Encapsulation and sustained release of curcumin

using superparamagnetic silica reservoirs." Chemistry 15(23): 5661-5665.

Choudhuri, T., S. Pal, et al. (2002). "Curcumin induces apoptosis in human breast

cancer cells through p53-dependent Bax induction." FEBS Lett 512(1-3): 334-

340.

ChromaDex (2003). Determination of Curcuminoids in Turmeric Extract by HPLC.

Churchill, M., A. Chadbum, et al. (2000). "Inhibition of intestinal tumors by curcumin

is associated with changes in the intestinal immune cell profile." J Sure Res

89(2): 169-175.

Constantinides, P. P. (1995). "Lipid microemulsions for improving dmg dissolution and

oral absorption: physical and biopharmaceutical aspects." Pharm Res 12(11):1561‘-1572.

Corporation, P. (2007). WinNonlin User's Guide Verion 5.2, Pharsight Corporation,

321 E. Evelyn Ave., 3rd Floor, Mountain View, California

Corsi, M. M., A. A. Bertelli, et al (1998). "The therapeutic potential of Aloe Vera in

tumor-bearing rats." Int J Tissue React 20(4): 115-118.

Craig, D. Q., S, A. Barker, et al. (1995). "An investigation into the mechanism of self

eraulsification using particle size analysis and low frequency dielectric

spectroscopy." International Journal of Pharmaceutics 114; 103-110.

Craig, D. Q., H. S. R, Lievens, et al. (1993). "An investigation into the physicochemical

properties of self emulsifying systems using low frequency dielectric

i w ....

Development o f Novel Fonnulations..,. References

spectroscopy, surface tension measurements and particle size analysis.

Internationai Journat of Pharmaceutics 96( I -3): i 47-155.

Ciii, J-, B. Yu, et al. (2009). "Enhancement of oral absorption of curcumin by self-

microemulsifying drug delivery systems." Int J Pharm 371(1-2): 148-155,

Cui, S. X., S. F. Nie, et al. (2009). "Preparation and evaluation of self-ralcroemulsifying

drug delivery system containing vinpocetine." Drug Dev Ind Pharm 35(5): 603-

611.

D'Ambrosio, S. M., R. Gibson-D'Ambrosio, et al. (2000). "Differential response of

normal, prenialignant and malignant human oral epithelial cells to growth

inhibition by chemopreventive agents." Anticancer Res 20(4): 2273-2280.Dai, J,, T. Nagai, et al. (2004). "pH-sensitive nanoparticles for improving the oral

bioavailability of cyclosporine A." Int. J. Pharm. 280(1-2): 229-240.

Damge, C., C. Michel, et ai. (1988). "New approach for oral administration of insulin

with polyalkylcyanoacrylate nanocapsules as drag carriers." Diabetes 37: 37.

Dance-Barnes, S. T., N. D. Kock, et al. (2009). "Lung tumor promotion by curcumin."

Carcinogenesis 30(6): 1016-1023.

Dandekar, P., R, Dhumal, et ai. (2010). "Toxicologicai evaluation of pH-sensitive

nanoparticles of curcumin: acute, sub-acute and genotoxicity studies." Food

Chan Toxicol 48(8-9): 2073-2089.

Dandekar, P. P., R. Jain, et al. (2010). "Curcumin-loaded hydrogel nanopaiticles:

application in anti-malarial therapy and toxicologicai evaluation." J Pharm Sol

99(12): 4992-5010.

Das, R. K., N. Kasoju, et al. (2010). "Encapsulation of curcumin in algiiiate-chitosan-

pluronic composite nanoparticles for delivery to cancer cells." Nanomedicine

6(1): 153-160.

Deeb, D., H. Jiang, et al. (2004). "Curcumin sensitizes prostate cancer cells to tumor

necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear

factor-kappaB through suppression of IkappaBalpha phosphorylation." Mol

CancerTher3(7): 803-812.

Deodhar, S. D., R. Sethi, et al. (1980). "Preliminary study on antirheumatic activity of

curcumin (diferuloyl methane)." Indian J Med Res 71: 632-634.

Devani, M., M. Ashford, et al. (2004). "The emulsification and solubilisation properties

of polyglycolysed oils in self-emulsifying formulations." J Pharm Pharmacol

56(3): 307-316.

~ i w ......

Development o f Novel Formukitions....References

Devasena, T-, K. N. Rajasekaran, et ai. (2003). "Anticarcinogenic effect of bis-l,7-(2-

hydroxyphenyl)-hepta-l,6-diene-3,5-dione a ciircumin analog on DMH-induced

coion cancer model." Pliarmaco! Re.s 47(2): 133-140.

f3har, M. L., M. M, Dhar, et al. (1968). "Screening of Indian plants for biological

activity: I." Indian J Exp Biol 6(4): 232-247.

Dhawan, B. N., M. P. Dubey, et ai. (1980). "Screening of Indian plants for biological

activity: Part IX." Indian Exp Biol 18(6): 594-606.

Di Mario, F., N. Stefani, et al. (2006). "A new curcumin-ba.sed one week therapy for

eradication of H. pylori infection." Dige.stive and Liver Disease 38(Supplement

l);S71"S71.

Divya, C. S. and M. R. Pillai (2006). "Antitumor action of curcumin in human

papillomavirus associated cells involves downregulation of viral oncogenes,

prevention of NFkB and AP-1 tran.slocation, and modulation of apoptosis," Mol

Carcinoe 45(5): 320-332.

Duan, J,, Y. Zhang, et al. (2010). "Synthesi,s and in vitro/in vivo anti-cancer evaluation

of curctimin-loaded chitosan/poIy(butyf cyanoacrylate) nanoparticles." fnt J

Phaaa 400(1-2): 211-220.

Eigner, D. and D. Scholz (1999). "Ferula asa-foetida and Curcuma longa in traditional

medical treatment and diet in Nepal." J Ethnopharmacol 67(1): 1-6.

El-Shabouri, M. H. (2002). "Positively charged nanoparticles for Improving the oral

bioavailability of cyclosporin-A." Int. J. Pharm. 249(1-2): 101-108.

Elattar, T. M. and A. S. Virji (2000). "The inhibitory effect of curcumin, genistein,

quercetin and cisplatin on the growth of oral cancer cells in vitro." Anticancer

Res 20(3A): 1733-1738.

FDA, U. (2010, 10/08/2010). "Generally Recognized as Safe (GRAvS)." 2010, from

http://www.fda.gov/Food/FoodIngredientsPackaging/GenerallvRecognizedasSa

feGRAS/defauit.htm.

FDA, U. (2010). "Inactive Ingredient Search for Approved Drug Products." 2010, from

http://www.acce.ssdata.fda.gov/scriDts/cder/iig/index.cfm.

Frank, N„ J. Knauft, et al. (2003). "No prevendon of liver and kidney tumors in Long-

Evans Cinnamon rats by dietary curcumin, but inhibition at other sites and of

metastases." Mutat Res 523-524: 127-135.

181

Developnwnl o f Novel Formulations. ...References

Frautsch}^ S. A., W. Hu, et al. (2001). "Phenolic anti-inflammatory antioxidant reversai

of Abeta-induced cognitive deficits and neuropathology." Neurobiol Aging

22(6): 993-1005.

Gaedeke, J., N. A. Noble, et al. (2004). "Cufcumin blocks rnuitiple sites of the TGF"

beta signaling cascade in renal ceJis." Kidney Int 66(1); 112-120.

Ganta, S. and M. Amiji (2009). "Coadministration of Paclitaxel and curcumin in

nanoemuision formulations to overcome multidrug resistance in tumor cell,s."

Mol Pharm 6(3): 928-939.

Gao, P., B. D. Rush, et al. (2003). "Development of a supersaturable SEDDS (S-

SIEDDS) formulation of paclitaxel with improved oral bioavailability." J Pharm

,Sd92(!2):2386..2398.Gao, Y., Z. Li, et al. (2010). "Preparation and characterization of intravenously

injectable curcumin nanosuspension." Daig Deliv.

Garcea, G., D. P. Berry, et al (2005). "Consumption of the putative chemopreventive

agent curcumin by cancer patients; assessment of curcumin levels in the

colorectum and their pharmacodynamic consequences." Cancer Epidemiol

Biomarkers Prev 14(1): 120-125.

(jershanik, T. and S. Benita (1996). "Positively charged self-emulsifying oil

formulation for improving the oral bioavailability of progestrone." Pharm Dev

Technol 1; 147--157.

Gershaniic, T. and S. Benita (2000). "Self-dispersing lipid formulations for improving

oral ab.sorption of lipophilUc drugs." Eur J Pharm Biopharm 50(1): 179-188.

Ghosh, M., A. T. Singh, et al. (2010). "Curcumin nanodisks: formulation and

characterization." Nanomedicine.

Giladi, N.,‘D. Kazanov, et al. (2010). "Curcumin potentiates the pro-'apoptotic effects of

sulindac sulfone in colorectal cancer." Expert Qpin Inve.stig Drugs 19 Suppl I:

Si 17-124.

Godddeeris, €., F. Cuppo, et a l (2006). "Light scattering measurements on

microemulsion: Estimation of droplet sizes." International Journal of

Pharmaceutics 3t2ri-2): 187-195.

Goel, A., A. B. Kummmakkara, et al. (2008). "Curcumin as "Curecumin": from kitchen

to clinic." Biochem Pharmacol 75(4): 787-809.

Goodman, L., A. Gilman, et al. (2006). Goodman and Gilman's the pharmacological

basis of therapeutics. McGravt'-Hill.

...

Devclopmeni o f Novel Formulatiom... .References

Govender, T.,, S. Stolnik, et, al. (1999). "PLGA nanoparticles prepared by

nanoprecipitaticm: drug loading and release studies of a water soluble drug." L

Control. Release 57(2); 171-185.

Guiu'rero, Q., E. AiJemann, et ai. (1998). "Preparation techniques and mechanisms of

fonTiation of biodegradable naaopardcles from preformed polymers." Drug Dev.

fnd. Pharm. 24: 1113-1128.

Gukovsky, f., Cl N. Reyes, et al. (2003). "Curcumin ameliorates ethanol and nonethanol

experimental pancreatitis." Am J Phvsiol Gastrointest Liver Physiol 284(1):

G85-9.5.

Guo, F. and C. J. Xu (2005). "[Progress on the study of mechanism of the direct action

of TCM bioactive components on ovarian cancer]." Zhongguo Zhone Xi Yi .fie

He Za Zhi 25( 12): 1! 40-1144.

Gupta, V., A. A.seh, et al. (2009). "Fabrication and characterization of silk fibroin-

derived curcumin nanoparticles for cancer therapy." Int .T Nanomedicine 4: 115-

122.

Gursoy, N., J. S. Garrigue, et a l (2003). "Excipient effects on in vitro cytotoxicity of a

novel paclitaxel .self-emulsifying drug delivery system." ,f Pharm Sci 92(12):

2411-2418.

Gururajan, M., T. Dasu, et ai. (2007). "Spleen tyrosine kinase (Syk), a novel target of

curcumin, is required for B lymphoma growth." J Immunol 178(1): 111-121.

Han, S. S., Y. S. Keum, et a l (2002). "Curcumin suppresses activation of NF-kappaB

and AP-1 induced by phorbol ester in cultured human promyelocytic leukemia

cells." J Biochem Mol Biol 35(3): 337-342.

Hans, M. L. and A. M. Lowman (2002). "Biodegradable nanoparticles for drug delivery

and targeting." Curr. Qpin. Solid State and Mater. Sci. 6: 319-327.

Harada, K., T. Okiyoneda, ct al. (2007). "Curcumin enhances cystic fibrosis

transmembrane regulator expression by down-regulating caireticulin." Biochem

Biophvs Res Commun 353(2): 351-356.

Hauss, D. J., S. E. Fogal, et al. (1998). "Lipid-based delivery systems for improving the

bioavaiiability and lymphatic transport of a poorly water-soluble LTB4

inhibitor." J Pharm Sci 87(2): 164-169.

Hecq, J., M. Deleers, et al. (2006). "Preparation and in vitro/in vivo evaluation of nano­

sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed

183

Development o f Novel I'ormulatkms....References

poorly water-soluble weak base." European Journai of Pharmaceutics and

Biopharniaceiitlcs 64(3); 360-368.

Hilchie, A. L., S. J. Fiuiong, et al. (2010), "Curciirain-induced apoptosis in PC3

prostate carcinoma cells is caspase-independt^nt and involves cellular ceramide

accumulation and damage to mitochondria." Nutr Cancer 62(3): 379-389.

Holt, P. R., S. Katz, et al, (2005). "Curcumiti therapy in. inflammatory bow'd disea.se: a

pi lot study." Dig Di.s Scl 50( 11): 2191 ~2193.

Hostanfika., K., G. Daum, et al. (2002),, "Cytostatic and apoptosis-iriducing activity of

boswellic acids toward malignant cell lines in vitro." Anticancer Res 22(5):

2853^2862.

Hour, T. C., J. Chen, ct ai. (2002). "Cisrcumin enhances cytotoxicity of

chemotherapeutic agents in prostate cancer cells by inducing p21(WAFl/CIPi)

and C/EBPbeta expressions and suppressing NF-kappaB activation." Prostate

51(3): 211-218.

Hu, X., B. N. Cao, et ai. (2002). "Attenuation of cell migration and induction of ceil

death by aged garlic extract in rat sarcoma cells." Int J Mol Med 9(6): 641-643.

Hoang, A. C., S. Y, Lin, et al. (2008). "Effects of curcumin on N-bis(2-hydroxypropyl)

nitrosamine (DHPN)-induced lung and liver tumorigenesis in BALB/c mice in

vivo." In Vivo 22(6): 781-785.

Ichiki, K., N, Mitani, et al. (2000). "Regulation of activator protein-1 activity in the

mediastinal lymph node metastasis of lung cancer." Clin Exp Metastasis 18(7):

539-545.

Ireson, C„ S, Orr, et al. (2001). "Characterization of metabolite. of the

chemopreventive agent curcumin in human and rat hepatocytes and in the rat in

vivo, and evaluation of their ability to inhibit phorbol ester-induced

prostaglandin E2 production." Cancer Res 61(3): 1058-1064.

Ireson, C, R., D. J. Jones, et al. (2002). "Metabolism of the cancer chemopreventive

agent curcumin in human and rat intestine." Cancer Epidemiol Blomarkers Prev

11(1): 105-111.

Itokawa, H., K. Takeya, et al. (1984), "Cell grovi/th-inhibitory effects of derivatives of

antituraor cyclic hexapeptide RA-V obtained from Rubiae radix (V)." Gann

75(10): 929-936.

184

D evelopm ent o f N ovel F o n u u ia tio n s. ...R tfe re n c ex

Jiiiswal. S. Kumar Gupta, et a l (2004). "Preparation of biodegradable cyclosporine

nanoparticles by high-pressure emulsification-solvent evaporation process." L

Control Release 96(!): 169-178.

Johnson, C. B. and A. N. Mattia. (2010). "840. Curcumin (WHO Food Additives Series

35)." 2010, from

http://www.inchem.Org/document.s/iecfa/iecmono/v35ie09.htm.

Johnson, S. M., P. Gulhati, et al. (2009). "Curcumin inhibits proliferation of colorectal

carcinoma by modulating Akt/mTOR signaling." Anticancer Res 29(8); 3185-

3190,

Jung, S., N. <3tberg, et al. (2006). "Innovative liposomes as a transfbllicular drug

delivery system: penetration into porcine hair follicles." .T Invest Dermatol

126(8); 1728-1732.

Kakkar, Y,, S. Singh, et al. (2010). "Exploring solid lipid nanoparticles to enhance the

oral bioavailiibility of curcumin." Mol Ntitr Food Res.

Kang, B. K., J. S. Lee, et al. (2004). "Development of seif-microemulsifying drug

delivery systems (SMEDDS) for oral bioavailability enhancement of

simvastatin in beagle dogs," Int J Pharm 274(1-2): 65-73.

Kelloff, G,, J. Crowell, et al (1996). "Clinical development plan: curcumin." J Cell

Biochem Suppl 26: 72-85.

Kempaiah, R. K. and K. Srinivasan (2002). "Integrity of erythrocytes of

hypercholesteroiemic rats during spices treatment," Mol Cell Biochem 236(1-

2): 155-161.

Khoo, S. M., A. J. Humberstone, et al. (1998). "Formulation design and bioavailabiiity

assessment of lipidic self-emulsifying formulations of halofantrine."

International Journal of Pharmaceutics 167(1-2): 155-164, ’

Kim, .1. Y. and Y. S. Ku (2000). "Enhanced absorption of indomethacin after oral or

rectal administration of a self-emulsifying system containing indomethacin to

rats." Int J Pharm 194(1); 81-89.

Kim, M. K„ G. J, Choi, et al. (2003). "Fungicidal property of Curcuma longa L.

rhizome-derived curcumin against phytopathogenic fungi in a greenhouse." J

Aerie Food Chcm31(6): 1578-1581.

Kim, T. H., H. H. Jiang, et ai. (2010). "Preparation and characterization of water-

soluble albumin-bound curcumin nanoparticle.s with improved antitumor

activity." Int J Pharm.

......T85'~.....

D evelopinenl o f N ovel F orm ula tionx.... R eferen ces

K,imura, M., M. Shizuki, et al. (1994). "Relationship between the molecular structures

and emulsification properties of edible oils.” .Btosci. Biotech. Biochem. 58;

1258-1261.

Kocbek, P., S. Baumgartner, et al. (2006). "Preparation and evahiation of

rianosuspensions for enhancing the dissolution of poorly soluble drugs,"

IntenuUionai Journa! of Pharmaceutics 3 1,2( 1 -2): 179-186.

Kohli, K,, S. Chopra, et al. (2010). "Self--eniulsifying drug delivery systems: an

approach to enhance oral bioavailabiiity.” Drug Discov Today.

Komrnuru, T. B. Gurley, et al. (2001). "Sclf-emulsifying drug delivery systems

(SEDDS) of coenzyme QIO; formulation development and bioavailabiiity

assessment." Int J Pharm 212(2): 233-246.

Konwarh, R., .f. P. Saikia, et al (2010). "'Poly(ethylene glycol)-magnetic nanoparticles-

curcumin' trio: directed morphogenesis and synergistic free-radical scavenging."

Colloids Surf B Biointerfaces 81.(2): 578-586.

Kumar, M. N. V, R., U. Bakowsky, et al. (2004). "Preparation and characterization of

cationic PLGA nanospheres as DNA carriers." Bioroateriais 25(10): 1771-1777.

Kuinar, V. V„ I), Chaudrasekar, et al. "Development and evaluation of nitrendipine

loaded solid lipid nanoparticles: Influence of wax and glyceride lipids on

plasma pharmacokinetics." International Journal of Pharmaceutics In Press,

Corrected Proof.

Kunnumakkara, A. B., P. Diagaradjane, et al. (2009). "Curcumin sensitizes human

colorectal cancer to capecitabine by modulation of cyclin Dl, COX-2, MMP-9,

VEGF and CXCR4 expression in an orthotopic mouse model." Int J Cancer

125(9): 2187-2197.

Lao, C. D., M. T, t. Ruffin, et a l (2006). "Dose escalation of a curcuminoid

formulation." BMC Complement Altern Med 6: 10.

Li, H., Y. Che, et a l (2002). "[Effects of curcumin on proliferation and apoptosis in

human hepatic cells]." Zhonghua Gan Zang Bing Za Zhi 10(6): 449-451.

Li, L., B. Ahnied, et al. (2007). "Liposomal curcumin with and without oxaliplatin:

effects on cell growth, apoptosis, and angiogenesis in colorectal cancer." Mol

Cancer Ther 6(4): 1276-1282.

Li, L., F. S. Braiteh, et al. (2005), "Liposome-encapsulated curcumin: in vitro and in

vivo effects on proliferation, apoptosis, signaling, and angiogenesis." Cancer

104(6): 1322-1,331.

.... ................ '

Devt'lopmetU o f Novel Formulations....References

iiixi, Cl P., I". Chu, et ai. (2001). "Tlie curry spice curcumin reduces oxidative damage

and amyloid pathology in an Alzheimer transgenic mouse." i Neurosci 21(21):

8370-8377.

Lioritas, A. and H. Yegcr (2004). "Curciiiriin and resveratrol induce apoptosis and

nuclear translocation and activation of p53 in human neuroblastoma."

Anticancer Res 24(2B): 987-998.

Liu, L„, R, Wang, et al. (2010). "Cloning and soluble expression of mature {alpha}-

luffin from Luffa cylindrica and its antitumor activities in vitro." Acta Biochim

Biophvs Sin (Shanghai) 42(8): 585-592.

lJu, Z. J,, G. Han, et al. (2009). "[Preparation and drug releasing property of curcumin

nanoparticles]." Zhong Yao Cai 32(2); 277-279.

Liversidge, G. G. and P, Conzentino (1995), "Drug particle size reduction for

decreasing gastric irritancy and enhancing absorption of naproxen in rats." Int.

J. Pharm. 125(2): 309-313.

Lii, P., Q. Tong, et ai. (2005). "Preparation of curcumin prodrugs and their in vitro anti-

tumor activitie,s." J Huazhong Univ Sci Technolog Med Sci 25(6): 668-670,

678.

Luo, ¥., D. Chen, et al. (2006). "Solid lipid nanoparticles for enhancing vinpocetine's

oral bioavailability." .lournal of Controlled Release 114(1); 53-59.

Mae, S. H,, M. Sofia, et al. (2008). "Selectivity of compounds isolated from the leaves

of Nerium indicum Mill, on various human cancer cell lines." Med J Malaysia

63 Suppl A: 24-25.

Mahady, G. B., S. L. Pendland, et al. (2002). "Turmeric (Curcuma longa) and curcumin

l/ihibit the growth of Helicobacter pylori, a group 1 carcinogen." Anticancer Res

22(6C): 4179-4181.

Maincent, P., R. L. Verge, et ai. (1986). "Disposition kinetics and oral bioavailability of

vincamine-loaded polyalky! cyanoacrylate nanoparticles." J. Pharm. Sci 75:

955-958.

Maiti, K., K. Mukherjee, et al. (2007). "Ctirciimin-phospholipid complex: Preparation,

therapeutic evaluation and pharmacokinetic study in rats." Int J Pharm 330(I--2):

155-163.

Marczylo, T. H., R. D. Verschoyle, et al. (2007). "Comparison of systemic availability

of curcumin with that of curcumin formulated vt'ith phosphatidylcholine."

Cancer Chemother Pharmacol 60(2): 171-177.

Developmenl o f Novel Fonmdutkms.... References

Malray-Devoti, J. (2006). Cancer Drug.s, Chelsea House Publishers.

Mazumdar, U. K., M. Gupta, et: al. (1997). "Antitumor activity of Hygrophila spinosa

on Ehrlich ascites carcinoma and sarcoma-180 induced mice." Indian .1 Exp Biol

35(5): 473-477,

Mehrotra, T. N. and G. Cardinali (1965). "Effect of Colchicine and Catharanthus

Ro.seus (Vinca Rosea) Alkaloids on Mitosis of Syrian Hamster Bone Marrow

Celis." Indian J Pathol Bacteriol 39: 98-102.

Meinzer, A., E. Muelier, et al (1995). "Microemulsions a suitable galenical approach

for the ab.sorption enhancement of low soluble drugs." B.T. Gattefosse 88: 21-

26.

Meliado, W., N. F. Magri, et ai. (1984). "Preparation and biological activity of taxol

acetates." Biochem Biophvs Res Commun 124(2): 329-336.

Merisko-Liversidge, E., G. G. Liversidge, et al. (2003). "Nanosiziiig: a formulation

approach for poorly-water-soluble compounds." Eur. .f. Pharmac. Sci. 18(2):

113420.

Moghaddaiii, S. J., P. Barta, et al. (2009). "Curcumin inhibits COPD-fike airway

inflammation and lung cancer progression in mice," Carcinogenesis 30(11):

1949-1956.

Molpeceres, J., M. Guzman, et al. (1996). "Application of central composite designs to

the preparation of polycaprolactone nanoparticie.s by solvent displacement." I

Pharm. Sci. 85(2): 206-213.

Mukhopadhyay, A., C. Bueso-Ramos, et al. (2001). "Curcumin downregulates cell

survival mechanisms in human prostate cancer cell lines." Oncogene 20(52):

7597-7609.

Mulik, R., K. Mahadik, et al. (2009). "Development of curcuminoids loaded poly(butyl)

cyanoacrylate nanoparticles; Physicochemical characterization and stability

study." Eur J Pharm Sci 37(3-4): 395-404.

Mulik, R. S., J. Monkkonen, et al. (2010). "Transferrin mediated solid lipid

nanoparticles containing curcumin; Enhanced in vitro anticancer activity by

induction of apoptosis." Int J Pharm 398(1-2): 190-203.

Naidu, K. A. and N. B. Thippeswamy (2002). "Inhibition of human low/ density

lipoprotein oxidation by active principles from .spices." Mol Cell Biochem

229(1-2); 19-23.

188

D eveloiimerit o f N ovel F orm ula tions....K eference.s

Nakagavva-Goto, K., K. Yamada, et al. (2007). "Antitumor agents. 258. Syntheses and

evaluation of dietary antioxidant-taxoid conjugates as novel cytotoxic agents."

Bioorg Med Chem Lett 17(18): 5204-5209.

National Insdtute of Medical Statistics (NIMS), I. (2010). "The Clinical Trials

Registry- India (CTRI)." 2010, ft'om http://l64.100.72.67/ClinicaitriaIs/.

National Institutes of Health (NIH), IJ. F. (2010). "Home - Clinicarrrials.gov." 2010,

frorn http ://c! i n ical tri als. gov/.

Navis, I , P. Sriganth, et al, (1999). "Dietary curcumin with cisplatin administration

modulates tumour marker indice.s in experimental fibrosarcoma." Pharmacol

Res 39(3): 175-179.

Nazzal, S., Smalyukh, II, et al (2002). "Preparation and in vitro characterization of a

eutectic based semisolid self-nanoemulsified drug delivery system (SNEDDS)

of ubiquinone: mechanism and progress of emulsion formation." Int J Pharm

235(1-2): 247-265.

Notarbartolo, M., P. Poma, et al. (2005). "Antitumor effects of curcumin, alone or in

combination w/ith cisplatin or doxorubicin, on human hepatic cancer ceils.

AnalyfJi.s of their po.ssible relationship to changes in NF-kB activation levels and

in lAP gene expression." Cancer Lett 224(1): 53-65.

O'Driscoll, C. M. (2002). "Lipid-based formulations for intestinal lymphatic delivery."

European journal of pharmaceutical sciences 15(5): 405-415.

O'Driscoll, C. M. and B. T. Griffin (2008). "Biopharmaceutical challenges associated

w'ith dnigs with low aqueous solubility-the potential impact of lipid-based

formulations." Adv Drug Deliv Rev 60(6): 617-624.

O'Sullivan-Coyne, G., G. C. O'Sullivan, et al. (2009). "Curcumin induces apoptosis-

independent death irt oesophageal cancer cells." Br J Cancer 101(9): 1585-1595.

O’Hara, T., Adrian Dunne, et al. (1998). "A review of methods used to compare

dissolution profile data." Pharmaceutical Science and Technology Today 5:

214-223.

Obitte, N. and A. Chukwu (2010). "The excipient usefulness of carbosil® and

Landolphia owariensis in two oil-based self-emulsifying formulations." Asian

Journal of Pharmaceutics 4(4): 213.

Odeberg, J. M., P. Kaufmann, et a l (2003). "Lipid drug delivery and rational

formulation design for lipophilic drugs with low oral bioavailability, applied to

cyelosporine." Eur J Pharm Sci 20(4-5): 375-382.

.....

D evelopm i'n t o f N o vel F o rm u la tio n s ....R e feren ces

Ohashi, Y., Y, Tsuchiya, et al. (2003). "Prevention of intrahepatic metastasis by

curcuniin in an ortiiotopic inipiantatiori model." Oncology 65(3): 250-258.

Onoue, S., H, Takahashi, et al. (2010). "Formulation design and photochemical studies

on nanocrystal solid dispersion of ciircmnin with improved oral bioavailability.''

J Pharm Sci 99(4): I87M881.

Padmaja, S. and T. N. Raju (2004). "Antioxidant effect of curciimin in selenium

induced cataract of Wistarrats." Indian J Esp Biol 42(6): 601-603.

Palamakiila, A. and M. A. Khan (2004). "Evaluation of cytotoxicity of oils used in

coenzyme (JIO Seli^emulsifying Drug Delivery Systems (SEDDS)." Int J Pharm

273(1-2): 63-73.

Pan, M. H., T. M. Hiuuig, et al. (1999). "Biotransformation of curciimin through

reduction and glucuronidation in mice." Drug Metab Dispos 27(4): 486-494.

Parsdya, U., M. K. Saini, et al. (2000). "Dietary curcumin prevents ocular toxicity of

naphthalene in rats." Toxicol Ixtt 115(3): 195-204.

Paradkar, A., A. A. Ambike, et al. (2004). "Characterization of curcumin-PVP solid

dispersion obtained by spray drying." International .fournal of Pharmaceutics

271(1-2): 281-286.

Paradkar, A„ A. A. Ambike, et al. (2004). "Chai'acterization of curcumin-PVP solid

dispersion obtained by spray drying." Int J Pharm 271(1-2): 281-286.

Parimala, R. and P. Sachdanandam (1993). "Effect of Plumbagin on some glucose

metabolising enzymes studied in rats in experimental hepatoma." Mol Cell

Biochem 125(1): 59-63.

Park, C., G, Y. Kim, et al. (2006). "Induction of G2/M arrest and inhibition of

cycIooxygenase-2 activity by curcumin in human bladder cancer T24 cells."

Oncol Rep 15(5): 1225-1231.

Patel, D. and K. K. Sawant (2009). "Self micro-emulsifying drug delivery system;

formulation development and biopharmaceutical evaluation of lipophilic drugs."

CuiT Drug Deliv 6(4): 419-424.

Patel, V. B„ S. Misra, et al. (2010). "Colorectal cancer: chemopreventive role of

curcumin and resveratrol." Nutr Cancer 62(7): 958-967.

Perkins, S., R. D. Verschoyle, et al. (2002). "Chemopreventive efficacy and

pharmacokinetics of curcumin in the min/+ mouse, a model of familial

adenomatous polyposis." Cancer Epidemiol Biomarkers Prev 11(6): 535-540.

190

D evclapm eni o f N avel F o m n ik itio n s ...R eferences

I’oliisa, K., A, N. Naiciu, et al. (2004). "Inhibition of B(a)P iiKluced strand breaks in

presence of cufcumin." Mutat Res 557(2): 203-213.

Poma, P., M. Notarbartolo, et al. (2007). ’’T!ie antitumor activities of curcumin and of

its isoxazole analogue are not affected by multiple gene expression changes in

an MDR model of the MCF-7 breast cancer cell line; analysis of the possible

molecular basis." Int J Mol Med 20(3): 329-335.

Ponchel, G., M, Montisd, et al. (1997). "Mucoadhesioii of colloidal particulate systems

in the gastro-intestinal tract." Ear. J. Pharrn. Biopharm. 44(1): 25-31.

Pouton, C. W. (2(K)0). "Lipid formulations for oral administration of drugs: non-

emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery

systems." Bur J Pharm Set 11 vSuppl 2: S93-98.

Ponton, C. W. (2006). "Formulation of poorly water-soluble drugs for oral

administration: physicochemical and physiological issues and the lipid

formulation classification system." Eur J Pharm Sci 29(3-4): 278-287.

Pouton, C. W. and C. J. Porter (2008), "Formulation of lipid-based delivery systems for

oral adrninistradon: materials, methods and strategies." Adv Drug Pcliv Rev

60(6); 625-637.

Pouton, C. W., M. G. Wakerly, et al. (1987). Self-emulsifying systems for oral delivery

of drugs. Int. Symp, Control Release Bioactive Materials.

Prashar, R., A. Kumar, et al. (1994). "Chernopreventive action by an extract from

Ocimum sanctum on mouse skin papillomagenesis and its enhancement of skin

glutathione S-transferase activity and acid soluble sulfydryl level." Anticancer

a ilfis , 5(5): 567-572.

Punithavathi, D., N. Venkatesan, et al (2003). "Protective effects of curcumin against

itmiodarone-induced pulmonary fibrosis in rats." Br J Pharmacol 139(7); 1342-

1350.

Quiles, J. L,, M. D. Mesa, et al. (2002). "Curcuma longa extract supplementation

reduces oxidative stress and attenuates aortic fatty streak development in

rabbits." Arterioscler Thromb Vase Biol 22(7): 1225-1231.

Quiroga, A,, P. L. Quiroga, et a l (2010). "Anti-breast cancer activity of curcumin on

the human oxidation-re,sistant cells ZR-75-1 with gamma-

glutamvltranspeptidase inhibition." J Exp Ther Oncol 8(3): 261-266.

Radhakrishna Pillai, G., A. S. Srivastava, et a l (2004). "Induction of apoptosis in

human lung cancer cells by curcumin." Cancer Lett 208(2): 163-170.

.................. ...

Development o jN ovel Foruudcitionx....References

Rafiee, P., H. Ogawa, et ai. (2003). "Isolation and characterization of human

esopiiageal inicrovascular endothelial cells: mechanisms of inflammatory

activation." Am J Physiol Gastrointest Liver Phvsiot 285(6); GI277-1292.

Ramachanclran, C., A. P. Resek, et al. (2010). "Potentiation of gemcitabine by Turmeric

Force in pancreatic cancer cell line.s." Oncol Rep 23(6): 1529-1535.

Rashmi, R., T. R. Santhosh Kumar, et al. (2003). "Human colon cancer cells differ in

their sensitivity to curcumin-induced apoptosi.s and heat .shock protect.s them by

inhibiting the release of apoptosi.s-inducing factor and caspaaes." FEBS Lett

.538(1-3): 19-24.

Ravindranath, V. and N. Chandrasekhara (1980). "Ab.sorption and tissue distribution of

curcumin in rats." Toxicology 16(3): 259-265.

Ravindranath, V. and N. Chandrasekhara (1981). "Metabolism of curcumin-studies

with [3H]curcumin." Toxicology 22(4); 337-344.

Reddy, V. V. and M. Sirsi (1969). "Effect of Abrus precatorius L. on experimental

tumors.” Cancer Res 29(7): 1447-1451.

Reiss, H. (1975). "Entropy induced di.spersion of bulk liquids." .T Colloid Interface Sci

53(1); 61-70.

Ritschel, W. and G. Kearns (1999). Handbook of basic pharmacokinetics- including

clinical application.s. American Pharmaceutical Association.

Rooney, S. and M. F. Ryan (2005). "Effects of alpha-hederin and thymoquinoiie,

constituents of Nigella sativa, on human cancer cell lines," Anticancer Res

25(3B): 2199-2204.

Roy, M., S. Chakraborty, et al. (2002). "Induction of Apoptosis in Tumor Cells by

Natural PhcnoHc Compounds." Asian Pac J Cancer Prev 3(!): 61-67.

Rukkumani, R., M. Sri Balasubashini, et al. (2002). "Comparative effects of curcntain

and photo-irradiated curcumin on alcohol- and polyunsaturated fatty acid-

induced hyperlipidemia." Pharmacol Res 46(3): 257-264.

Russell-Jones, G. L. Arthur, et al. (1999). "Vitamin B12-mediated transport of

nanoparticles across Caco-2 ceils." Int. J. Pharm. 179(2): 247-255.

Sakurna, S., N. Suzuki, et al. (1997). "Oral peptide delivery using nanoparticles

composed of novel graft copolymers having hydrophobic backbone and

hydrophilic branches." Int. J. Pharm. 149(1): 93-106.

Sanchez, Y„ G. P. Simon, et al. (2010). "Curcumin stimulates reactive oxygen species

production and potentiates apoptosis induction by the antitumor drugs ai'senic

192“""..

Development o f Novel Formulations....References

trioxidc and lonidamine in iiunian myeloid leukemia ceil lines." J Phannacol

Exp Ther 335(1): 114.123.

Savidge, T. C, M. W. Smith, et al, (1991). "Salmonella-induced M-cell formation in

gerai-free mouse Peyer'.s patch tissue." Am. J. Path 139; 177-184,

Setthaciieewakul, S., S. Mahattanadul, et al. (2010). "Development and evaluation of

self-microemulsifying liquid and pellet formulations of curcuinin, and

absorption studies in rats." Eur J Pharm Biooharm.

Shafiq, S., F. Sliakeel, et al. (2007). "Development and bioavailability assessment of

ramipril nanoeniulsion formulation." Eur J Pharm Biooharm 66(2); 227-243.

Shah, N. H., M. T. Carvajal, et al. (1994). "Self emulsifying drug delivery systems

(SEDDS) with poiyglycolyzed glycerides for improving in vitro dissolution and

oral absorption of lipophillic drugs." International Journal of Pharmaceutics

106(1); 15-23.

Shaikh, L, D. D. Ankoia, et al (2009). "Nanoparticfe encapsuiation improves oral

bioavailability of curcumin by at least 9-foid when compared to curcumin

administered with piperine as absorption enhancer." Eur J Pharm Sci 37(3-4):

223^230.

Shao, Z. M., Z. Z. Shen, et al. (2002). "Curcumin exertis multiple suppressive effects on

human breast carcinoma cells." Int J Cancer 98(2): 234-240.

Sharma, R. A,, S. A. Euden, et al. (2004). "Phase I clinical trial of oral curcumin:

biomarkers of systemic activity and compliance." Clin Cancer Res 10(20):

6847-6854.

Sharma, R. A., C. R. Ireson, et til. (2001). "Effects of dietary curcumin on glutathione

S-transferase and malondialdehyde-DNA adducts in rat liver and colon mucosa:

relationship with drug levels." Clin Cancer Res 7(5): 1452-1458.

Sharma, R. A., W. P. Steward, et al. (2007). "Pharmacokinetics and pharmacodynamics

of curcumin." Adv E x p Med Biol 595: 453-470.

Shicheng, Y., G. R. Neslihan, et al (2004). "Enhanced oral absorption of Paclitaxel in a

novel self microemulsifing drug delivery sysytem with or without concomittant

use of P-Glycoprotein inhibitors." Pharm Res 21(2): 261-270.

Shishodia, S., P. Potdar, et al. (2003). "Curcumin (difeniloylmethane) down-regulates

cigarette smoke-induced NF-kappaB activation through inhibition of

IkappaBalpha kinase in human lung epithelial cells: correlation with

193

Development v f Novel Fommlalions....References

.suppression of COX-2, MMP-9 and cyclin Dl." Carcinogenesis 24(7); 1269-

1279.

Shoba, (3., D. Joy, et al. (1998). "Influence of pipeline on the pharmacokinetics of

curcurairi in animals and human volunteers." Planta Med 64(4): 353-356.

Silva, B. F., E. F. Marques, et al. (2(H)9). "Size, shape, and charge of sait-free

catanionic microemulsion droplets: a .sraall-angle neutron scattering and

modeling study." J Phvs Chem B 113(30): 10230-10239.

Singh, B., S. Bandopadhyay, et al. (2009). "Self-emulsifying drug delivery systems

(SEDDS): formulation development, characterization, and applications." Crit

Rev Ther Drug Carrier Svst 26(5); 427-521.

Singh, M. and N. Singh (2010). "Curcumin counteracts the proliferative effect of

estradiol and induces apoptosis in cervical cancer cells." Mol Cell Biochem.

Singh, S. and M. Bakshi (2000). "Guidance on conduct of stress tests to determine

inherent stability of drugs." Pharmaceutical Technology Online(April): 1-14.

Sinha* R., D. E. Anderson, et al. (2003). "Cancer risk and diet in India." J Postgrad Med

49(3): 222-228.

Skommer, J., D. Wlodkowic, et al. (2006). "Cellular foundation of curcumin-induced

apoptosis in follicular lymphoma cell lines." Exp Hematol 34(4); 463-474.

Song, C. X., V. Labhasetwar, et al. (1997). "Formulation and characterization of

biodegradable nanoparticles for intravascular local drug delivery." J. Control.

Release 43(2-3): 197-212.

Sou, K., S, Inenaga, et al. (2008). "Loading of curcumin into macrophages using lipid-

based nanoparticles." Int J Pharm 352(1-2): 287-293.

Sou, K., B. Oyajobi, et al. (2009). "Characterization and cytotoxicity of self-organized

’ assemblies of curcumin and amphiphatic poly(ethylefie glycol)." J Biomed

Nanotechnol 5(2): 202-208,

Sreejayan and M. N. Rao (1997). "Nitric oxide scavenging by curcuminoids." J Pharm

Pharmacol 49(1): 105-107.

Srinivasan, P. and B. Libbus (2004). "Mining MEDLINE for implicit links between

dietary substances and diseases." Bioinformatics 20 Suppl 1:1290-296.

Stankovic, I. (2004). "Curcumin ~ Chemical and Technical Assessment (CTA)." 61st

JECPA 2004. 2010, from

ftp://ftD.fao.org/es/esn/iecfa/cta/CTA 61 Curcumin.pdf.

194

Development o f Novel P'orinidations,...References

,Su, C. C., J. S. Yang, ec al. (2,010). "Curcumin inhibits human lung large cell carcinoma

cancer tumour growth in a murine xenograft model." Phvtother Res 24(2): 189-

192,

Subramanian, N,, S. Ray, et al. (2004). "Formulation design of seif-microemulsifying

drug delivery systems for improved oral bioavailabiiity of ceiecoxib." Biol

Pharm Bull 27(12); 1993-1999.

Suryanarayana, P., K. Krishnaswamy, et al. (2003). "Effect of curcumin on galactose-

induced cataractogenesis in rats." Mol Vis 9: 223-230.

Swenson, E. S., W. B. Milisen, et al. (1994). "Intestinal permeability enhancement;

efficacy, acute local toxicity and reversibility." Pharm Res 11(8); 1132-1142.

Syu, W. J., C. C. Shen, et al. (1998). "Cytotoxicity of curcuminoids and some novel

compounds from Curcuma zedoaria." J Nat Prod 61(12): 1531-1534.

Takeuchi, H., H. Yamamoto, et ai. (2001). "Mucoadhe.sive nanoparticulate systems for

peptide diiig delivery." Adv. Drug Del. Rev. 47(1): 39-S4.

Tammariello, A. E, and J. A. Milner (2010). "Mouse models for unraveling the

importance of diet in colon cancer prevention." J Nutr Biochcm 21(2); 77-88.

Teiten, M. H., F. Gaascht, et al. (2010). "Chemopreventive potential of curcumin in

prostate cancer," Genes Nutr 5(1): 61-74.

Tharakan, S. T., T. Inamoto, et a l (2010). "Curcumin potentiates the antitumor effects

of gemcitabine in an orthotopic model of human bladder cancer through

suppression of proliferative and angiogenic biomarkers." Biochem Pharmacol

79(2): 218-228.

Thompson, K. H., K. Bohmerie, et al. (2004). "Complementary inhibition of

synoviocyte, smooth muscle cell or mouse lymphoma cell proliferation by a

vanadyl curcumifl complex compared to curcumin alone." J Inorg BioChem

98(12); 2063-2070.

Tiyaboonchai, W., W. Tungpradit, et al. (2007). "Formulation and characterization of

curcuminoids loaded solid lipid nanopaiticles." Int J Pharm 337(1-2); 299-306.

Tobio, M., A. Sanchez, et al (2000). "The role of PEG on the stability in digestive

fluids and in vivo fate of FEG-PLA nanoparticles following oral

administration." Colloids ans Surfaces B: Biointerfaces 18: 315-323.

Tomida M., H. Ohtake, et al. (2008). "Stat3 up-regulates expression of nicotinamide

N-methyltransferase in human cancer cells." J Cancer Res Clin Oncol 134(5):

551-559.

Development o f N o vel Formulations.. ..References

Tonnesen, H. H. and J. Karlsen (1985). "Studies on curcumin and curcuminoids. V

■Alkaline degradation of curcumin." Z Lebensrn Unters Forsch 180(5): 132-134.

ToiineserL, H. H. and J. Karlsen (1985). "Studies on curcumin and curcuminoids. VL

Kinetics of curcumin degradation in aqueous solution." Z Leben.sm Unters

Forsch 180(5): 402-404.

Tunstall, R. G., R. A. Sliarma, et ai. (2006). "CyclooxygenawSe-2 expression and

oxidative DNA adducts in murine intestinal adenomas; modification by dietary

curcumin and implications for clinical trials." Eur J Cancer 42(3): 415-421.

Ukii, A., S. Maity, et al. (2003). "Curcumin, the major component of food flavour

turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced

colitis." BrJ Pharmacol 139(2): 209-218.

USFDA. (1997, September, 1997). "Guidance Ibr Industry SUPAC-MR: Modified

Release Solid Oral Dosage Forms." Retrieved Feb. 20, 2004, from

h«:p://wwvi^.fda.gov/cdcr/guidancc/index.hl:m.

USFDA (2001). Guidance For Industry - Bioanalytical Method Validation. F. a. D. A.

U.S. Department of Health and Human Services, Center for Drug Evaluation

and Research, Center for Veterinary Medicine. Rockville, MD.

van't Land, B., N. M. Blijievens, et al. (2004). "Role of curcumin and the inhibition of

NF-kappaB in the onset of chemotherapy-induced mucosal barrier injury."

Leukemia 18(2); 276-284.

Vandervoort, J. and A. Ludwig (2002). "Biocompatible stabilizers in the preparation of

PLGA nanoparticles: a factorial design study," Int. J. Pharm. 238(1-2): 77-92.

Venkatesh, G., M. L Majid, et al "In vitro and in vivo evaluation of self-

microemulsifying drug delivery system of buparvaquone." Drug Dev Ind

Pharm.

Vonderscher, J, and A. Meinzer (1994). Rationale for the development of Sandimmune

Neoral. Transplantation proceedings.

Vyas, S. P. and R. K. Khar (2002). Submicron Emulsion. Targeted and controlled drug

delivery novel caitiers systems. New Delhi, CBS publishers and distributors:

291-294.

Wahlang, B., Y. B. Pawar, et al. (2010). "Identification of permeability-related hurdles

in oral delivery of curcumin using the Caco-2 cell model." European Journal of

Pharmaceutics and Biopharmaceutics.

196

Development o f Novel Farnudatkms....References

Wiihlstrorn, B. and G. Bletmow (1978). "A study on the fate of curcurnin in the rat."

Acta Pharmacol Toxicol ('Coperih) 43(2); 86-92.

Wang, W., FI Zhatig, et al. (2010). "[Anticancer activities of curcumin on human

hepatocarcinoma ceil line Slc-hep-1]," Zhongguo Zhong Yao Za Zhi 35(4): 485-

488.

Wang, y. J., M. H. Pan, et al. (1997). "Steibility of curcumin in buffer solutions and

characterization of its degradation products." j Pharm Biomed Anal 15(12):

1867-1876.

Wargovich, M. .1., C. D. Chen, et al. (1996). "Aberrant crypts a.s a biomarker Ibr colon

cancer: evaluation of potential chemopreventive agents in the rat." Cancer

Epidemiol Bioinarkers Prev 5(5): 355-360.

Wax, A., J. W. Pyhtila, et al (2005). "Prospective grading of neoplastic change in rat

e.sophagus epithelium using angle-resolved iow-coherence interferometry." J

Biomed Opt 10(5); 051604.

Wei, L., P. Sue, et al. (2005), "Preparation and evaluation of SEDDS and SMEDDS

containing carvedilol." Drug Dev Ind Pharm 31(8): 785-794.

Wei, S. C., Y, S. Lin, et al. (2004). "Comparison of the anti-proliferation and apoptosis-

induction activities of sulindac, celecoxib, curcumin, and nifedipine in

mismatch repair-deficient cell lines." J Formos Med Assoc 103(8): 599-606.

Werkley, M. G., C. W. Poutoii, et al. (1986). "Self einulsifiaction of vegetable oil-non~

ionic surfactant mixtures," ACS Svmp. Series 311: 242-255.

White, E. L., L. J. Ross, et al. (1998). "Screening of potential cancer preventing

chemicals for induction of glutathione in rat liver cells." Oncol Rep 5(2): 507-

512.

WHO. (2009). "Cancer, Fact sheet N“297." Retrieved'09.11.2010, 2010, from

http://vyww.who.int/mediacentre/faclsheets/fs297/en/print.html.

WHO. (2010). "Welcome to the WHO ICTRP." 2010, from

http://www.who.int/ictrp/en/.

Wiener, C., E. Braunwald, et al, (2004). Harrison's principles of internal medicine: self-

assessment and board review. McGraw-Hill, Medical Pub, Division.

Wijnands, M, V., M, J. van Erk, et al. (2004). "Do aberrant crypt foci have predictive

value for the occurrence of colorectal tumours? Potential of gene expression

profiling in tumours." Food Chem Toxicol 42(10): 1629-1639.

197

D evelopm ent ojN ovel Fonnulations,...References

Wu, W., J. Shen, et al. (2010). "Water-dispersible multifunctional hybrid nanogels for

combined curcumin and photothermal therapy," BioiTiateriais.

Wu, X., J. Xu, et af. (2010). ''Self-microernulsifying drug delivery system improves

curcumin dissolution and bioavailability." Drug Dev Ind Pharm.

Wu, Y„ A. Loper, et al. (2004). "The role of biopharmaceutics in the development of a

clinical nanoparticle formulation of MK-0869; a Beagle dog model predicts

improved bioavaiiability and diminished food effect on absorption in human."

Int. J, Pharm. 285(1-2): 135-146.

Xu, D. H,, S. Wang, et al, (2008). "[StudicK on solubility enhancement of curcumin by

polyvinylpyrrolidione K30]." Zhong Yao Cai 31(3); 438-442.

Yallapu, M. M., B. K. Gupta, et al. (2010). "Fabrication of curcumin encapsulated

PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells."

J Colloid Interface Sci 351(1): 19-29-

Yaliapu, M. M., D. M. Maher, et al. (2010). "Curcumin induces chemo/radio-

sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian

cancer cell grovi/th." J Ovarian Re.s 3: 11.

Yang, K. Y., L. C. Lin, et al. (2007). "Oral bioavaiiability of curcumin in rat and the

herbal analysis from Curcuma longa by LC-MS/MS." J Chromatogr B Analvt

Technol Biomed Life Sci 853(1-2): 183-189.

Yen, F. L., T. H. Wu, et al. (2010). "Curcumin nanoparticles improve the

physicochemical properties of curcumin and effectively enhance its antioxidant

and antihepatoma activities." J Aerie Food Chem 58(12): 7376-7382.

Yu, Y., S. S. Kanwar, et al (2009). "Elimination of Colon Cancer Stem-Like Cells by

the Combination of Curcumin and FOLFOX." Transl Oncol 2(4): 321-328.

Zhang, C., B. Li, et al. (2010). "Curcumin selectively induces apoptosis in cutanetius T-

cell lymphoma cell lines and patients' PBMCs: potential role for STAT-3 and

NF-kappaB signaling." J Invest Dermatol 130(8): 2110-2119.

Zhao, B. L., X. J. Li, et al. (1989). "Scavenging effect of extracts of green tea and

natural antioxidants on active oxygen radicals." Cell Biophvs 14(2): 175-185.

Zheng, M., S. Ekmekcioglu, et al. (2004). "Inhibition of nuclear factor-kappaB and

nitric oxide by curcumin induces G2/M cell cycle arrest and apoptosis in human

melanoma cells." Melanoma Res 14(3): 165-171.

Zheng, Z., X. Zhang, et al. (2010). "Sonication-assisted synthesis of polyelectrolyte-

coated curcumin nanoparticles." Langmuir 26(11): 7679-7681..... ---====1== ^

D t’vtdopitH'iil o f N o vel I'orimilcilioiis. ..Reference.s

Ihu., X. M. Siiii, et al. (2010). "|Prepar;jtion and characterization of curcumin

polybutylcyanoacrylate nanoparticles].'' ZhoriK Yao Cai 33(5): 797-80!.

199